Fig. 1.

MAP2K4 mutant cell lines respond to MEK inhibition. a A breast cancer cell line panel including two MAP2K4 mutant breast cancer cell lines (red) and nine wild-type breast cancer cell lines (black) were cultured in medium containing the indicated concentration of selumetinib for two weeks. After this, cells were fixed and stained. b MAP2K4 mutant (red) and wild-type (black) cell lines were cultured in medium containing the indicated concentration of selumetinib for two weeks. After this, cells were fixed and stained. c Cell proliferation curves of 4 breast cancer cell lines. Two MAP2K4 mutant breast cancer cell lines (red) and two wild-type breast cancer cell lines (black) were cultured in medium containing the indicated concentration of selumetinib. Percent confluence over time was monitored using an IncuCyte real-time imager. d,e Four breast cancer cell lines of indicated MAP2K4 mutation status were cultured in medium containing the indicated concentration of trametinib (c) or SCH772984 (d) for 2 weeks. After this, cells were fixed and stained